Please assess the completion status of the following clinical trial:

Trial Title: Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Diagnosis of CLL/SLL which is made according to the updated criteria of the NCI Working Group~* Cohort 1:Treatment naive CLL/SLL patients~* Cohort 2: Subjects must be receiving treatment ibrutinib for at least 6 months prior to administration of the first vaccine dose~* Cohort 3: Subjects must be receiving acalabrutinib for at least 6 months prior to administration of the first vaccine dose~* No active, symptomatic VZV or herpes zoster infection within 12 months prior to vaccination~* No exposure to the live VZV vaccine (ZOSTAVAX) within 12 months prior to vaccination~* No prior exposure to the SHINGRIX vaccine~* Age greater than or equal to 18 years.~* ECOG performance status of 0-2~* Able to comprehend the investigational nature of the protocol and provide informed consent~EXCLUSION CRITERIA:~* Female patients who are currently in pregnancy~* Any uncontrolled active systemic infection~* Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk~* Severe allergic reaction to any component of SHINGRIX.~* Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination.~* Concomitant use of immunosuppressive agents (e.g. steroids, radio~therapy, chemotherapy)~* Hereditary or acquired immunodeficiency syndrome unrelated to chronic lymphocytic leukemia~* Non-English speaking individuals will be excluded from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Chronic Lymphocytic Leukemia Patients That Are Treatment Naive (Type: EXPERIMENTAL): Chronic Lymphocytic Leukemia Patients That Are Treatment Naive will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
- Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib (Type: EXPERIMENTAL): Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
- Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib (Type: EXPERIMENTAL): Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).